A biomarker could help identify patients with lung cancer who are most likely to benefit from treatment with AstraZeneca and Daiichi Sankyo's TROP2-directed drug datopotamab deruxtecan (Dato-DXd). The ...

AstraZeneca and Daiichi Sankyo have moved swiftly to file for FDA approval of a second indication for their TROP2-directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd), this time for ...

McDonald's Grinch meal vs. Burger King's SpongeBob menu: Here's the obvious winner Drone video captures flooded Puyallup River as Washington issues warning House passes $901B military defense bill ...

Meta is encouraging users to verify themselves to unlock more features or engagement with their posts. Endangered species are being sold online with UK-based firms illegally supplying seahorses, a BBC ...

ApexOnco and other media outlets reported that the FDA has placed a partial clinical hold on the phase III IDeate-Lung02 trial after more patients died from interstitial lung disease than anticipated; ...

Download ProShares UltraShort Dow30 stock data: historical DXD stock prices from MarketWatch.

Tristan is an independent science writer based in Metro Manila, with more than eight years of experience writing about medicine, biotech and science. He can be reached at [email protected], ...